Zafgen Announces Oral and Poster Presentations at the 22nd European Congress on Obesity Read more about Zafgen Announces Oral and Poster Presentations at the 22nd European Congress on Obesity Zafgen to Host Conference Call to Discuss First Quarter 2015 Financial Results Read more about Zafgen to Host Conference Call to Discuss First Quarter 2015 Financial Results Zafgen Reports Fourth Quarter and Full Year 2014 Financial Results Read more about Zafgen Reports Fourth Quarter and Full Year 2014 Financial Results Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2014 Financial Results Read more about Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2014 Financial Results Zafgen Announces New Weight Loss and Safety Data from Phase 2 Trial of Beloranib in Hypothalamic Injury Associated Obesity at ENDO 2015 Read more about Zafgen Announces New Weight Loss and Safety Data from Phase 2 Trial of Beloranib in Hypothalamic Injury Associated Obesity at ENDO 2015 Zafgen Joins NORD to Support Rare Disease Day(R) Read more about Zafgen Joins NORD to Support Rare Disease Day(R) Zafgen to Present at Cowen and Company 35th Annual Health Care Conference Read more about Zafgen to Present at Cowen and Company 35th Annual Health Care Conference Zafgen to Present at the 2015 RBC Capital Markets Conference Read more about Zafgen to Present at the 2015 RBC Capital Markets Conference Zafgen to Present at the 2015 Leerink Global Healthcare Conference Read more about Zafgen to Present at the 2015 Leerink Global Healthcare Conference Zafgen Announces Closing of Public Offering of Common Stock and Full-Exercise of Option to Purchase Additional Shares Read more about Zafgen Announces Closing of Public Offering of Common Stock and Full-Exercise of Option to Purchase Additional Shares Pagination First page « First Previous page ‹ Previous … Page 15 Page 16 Page 17 Page 18 Current page 19 Page 20 Page 21 Page 22 Page 23 … Next page Next › Last page Last » Subscribe to
Zafgen Announces Oral and Poster Presentations at the 22nd European Congress on Obesity Read more about Zafgen Announces Oral and Poster Presentations at the 22nd European Congress on Obesity
Zafgen to Host Conference Call to Discuss First Quarter 2015 Financial Results Read more about Zafgen to Host Conference Call to Discuss First Quarter 2015 Financial Results
Zafgen Reports Fourth Quarter and Full Year 2014 Financial Results Read more about Zafgen Reports Fourth Quarter and Full Year 2014 Financial Results
Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2014 Financial Results Read more about Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2014 Financial Results
Zafgen Announces New Weight Loss and Safety Data from Phase 2 Trial of Beloranib in Hypothalamic Injury Associated Obesity at ENDO 2015 Read more about Zafgen Announces New Weight Loss and Safety Data from Phase 2 Trial of Beloranib in Hypothalamic Injury Associated Obesity at ENDO 2015
Zafgen Joins NORD to Support Rare Disease Day(R) Read more about Zafgen Joins NORD to Support Rare Disease Day(R)
Zafgen to Present at Cowen and Company 35th Annual Health Care Conference Read more about Zafgen to Present at Cowen and Company 35th Annual Health Care Conference
Zafgen to Present at the 2015 RBC Capital Markets Conference Read more about Zafgen to Present at the 2015 RBC Capital Markets Conference
Zafgen to Present at the 2015 Leerink Global Healthcare Conference Read more about Zafgen to Present at the 2015 Leerink Global Healthcare Conference
Zafgen Announces Closing of Public Offering of Common Stock and Full-Exercise of Option to Purchase Additional Shares Read more about Zafgen Announces Closing of Public Offering of Common Stock and Full-Exercise of Option to Purchase Additional Shares